Alveolar capillary dysplasia with misalignment of the pulmonary veins (ACD/MPV) is a rare and lethal disorder mainly involving the vascular development of the lungs. Since its first description, significant achievements in research have led to a better understanding of the underlying molecular mechanism of ACD/MPV and genetic studies have identified associations with genomic alterations in the locus of the transcription factor FOXF1. This in turn has increased the awareness among clinicians resulting in over 200 cases reported so far, including genotyping of patients in most recent reports. Collectively, this promoted a better stratification of the patient group, leading to new perspectives in research on the pathogenesis. Here, we provide an overview of the clinical aspects of ACD/MPV, including guidance for clinicians, and review the ongoing research into the complex molecular mechanism causing this severe lung disorder.
The clinical presentation of alveolar capillary dysplasia with misalignment of the pulmonary veins (ACD/MPV) is characterized by respiratory distress and cyanosis caused by severe pulmonary hypertension (PH) and insufficient oxygen uptake. [1] [2] [3] Ninety-five percent of ACD/MPV patients are born at full term with normal birth weights and Apgar scores 4, 5 and most patients develop symptoms within the first 24 h of life. 1, 6, 7 In up to 80% of the cases, associated malformations are found for which surgery is occasionally needed. 3, [8] [9] [10] [11] [12] [13] [14] These malformations predominantly affect the gastrointestinal tract, but also affect the cardiovascular and urogenital system. [2] [3] [4] [5] 9, 15, 16 Irrespective of the co-morbidities, the mortality of ACD/MPV is almost 100%. The vast majority succumb to hypoxemic respiratory failure within days to weeks after presentation despite receiving supportive care including extracorporeal membrane oxygenation (ECMO). 4, 12, [17] [18] [19] [20] [21] [22] [23] [24] Atypical, milder cases of ACD/MPV patients that present after 24 h of life or survive beyond the neonatal period have sporadically been described and will be discussed in the histology section.
Incidence
Since ACD/MPV was first described in 1981, over 200 cases have been reported. 3, 25 In 2000, Al-Hathlol et al. reported two ACD/MPV patients among 226 infants autopsied over a 10-year period in the province of Manitoba, Canada. 4 During these 10 years, the total number of deliveries was 170,000, with 340 infants dying within the neonatal period.
It is unclear whether other ACD/MPV cases were among the remaining deceased neonates because an autopsy or biopsy is needed for confirmation. Based on this study, the incidence can be estimated at approximately 1/100,000. In The Netherlands, the incidence can be estimated at 1/200,000 if calculated from the total number of ACD/MPV patients (20) diagnosed in either the Radboudumc Amalia Children's Hospital Nijmegen or the Sophia Children's Hospital Rotterdam since 1993 and the total number of living births during this period (4.3 million 26 ). However, also in The Netherlands, it is likely that ACD/MPV is underdiagnosed and sometimes misdiagnosed as idiopathic PH due to the lack of autopsies.
Diagnosis
The current gold standard to unambiguously diagnose ACD/ MPV is histological examination of the lungs. In the majority of studies, most cases were diagnosed postmortem by autopsy. 4, 5, 27 In one study, 85% of cases were diagnosed premortem by open lung biopsy. 1 In this study, the median time from admission to lung biopsy was 6.5 days. Of neonatal patients who underwent an open lung biopsy during ECMO therapy in the Sophia Children's Hospital Rotterdam or the Radboudumc Amalia Children's Hospital Nijmegen, 32% were diagnosed with ACD/MPV. In all these patients, treatment was withdrawn due to futility. In order to avoid unnecessary and expensive ECMO treatment, it is recommended to perform a lung biopsy before starting ECMO therapy or, if it has been initiated already, within the first week of ECMO. 28 Considering the non-uniformly distribution of lung involvement observed in some patients, it is recommended to obtain more than one lung sample to avoid false-negatives.
Echocardiography is used to confirm PH and to exclude structural cardiovascular abnormalities. 1, 4, 7, 10, 18, 19, 21, 29 An X-ray of the lungs does not show features specific for ACD/MPV, but can show unspecific diffuse haziness or pneumothoraces, most likely caused by mechanical ventilation. 4, 7, 10, 18, 19, 29 A computed tomography (CT) scan may show bilateral widespread ground-glass infiltrates with septal line thickening, 12, 21 while a CT angiography does not result in the diagnosis either due to the limitations of imaging most peripheral capillaries of the lung. Photoacoustic imaging, however, is able to perform molecular imaging at a high resolution inside different tissues and therefore overcomes the limitations of a CT angiography. So far, photoacoustic imaging has only been used in biomedical research settings, but since studies in humans are very promising, it could provide an excellent tool to diagnose ACD/MPV in the future. 30 During pregnancy, there are no clinical signs associated with ACD/MPV. However, if there is a high suspicion for ACD/MPV, for instance after an earlier familial case, fetal genetic testing for deletions and mutations in the FOXF1 locus could contribute to an early diagnosis. 16, 31 In addition, a decreased total fetal lung volume (FLV) measured by prenatal magnetic resonance imaging (MRI) and ultrasound together with a lowered MRI signal intensity can be used to detect fetal pulmonary hypoplasia associated with multiple diffuse lung developmental disorders among others, including ACD/MPV. 32 An early detection of ACD/MPV allows adequate prenatal counseling regarding the dismal prognosis although the postnatal clinical course must be observed as it differs between patients. Histological examination will be necessary to confirm the diagnosis.
Histology
On gross examination, the lungs in cases of ACD/MPV appear bulky with up to a threefold increase in expected weight due to increased interstitial tissue. [33] [34] [35] The most significant differences between ACD/MPV and healthy lungs are noted on a microscopic level. In normal lungs, the alveolar capillaries are in close contact with the alveolar epithelium lined by flattened type 1 pneumocytes to provide sufficient gas exchange. In cases of ACD/MPV, the lung tissue is characterized by diffuse thickening of interalveolar septa and marked reduction of pulmonary alveolar capillaries. In addition, these scanty alveolar capillaries are located away from the alveolar epithelium which is predominantly composed of hyperplastic cuboidal type 2 pneumocytes (Fig. 1a) . [3] [4] [5] [33] [34] [35] Typically, in cases of ACD/MPV, the walls of small peripheral pulmonary arteries are thickened due to hypertrophic smooth muscle cells in the media (Fig. 1b) . Further, the majority of ACD/MPV patients present with peripheral veins in the bronchovascular bundle adjacent to the pulmonary arteries outside the interlobular septa while normally they are located within the septa. This phenomenon is called ''misalignment of the pulmonary veins'' (Fig. 1c) .
It is postulated that the milder phenotype of atypical ACD/MPV patients, including late presenters and longterm survivors, is correlated with the extent of affected lung tissue. 12, [19] [20] [21] 24, 36 Although a few atypical patients with diffuse histological findings similar to the typical patients have been described, 18 ,22 a very recent study showed a heterogeneous non-uniform distribution of histological findings in all atypical ACD/MPV patients. 36 Nevertheless, correlating the histological features with phenotypical differences between patients remains difficult due to factors such as incomplete autopsy records, varying co-existing malformations, and variations in treatment, especially concerning treatment withdrawal. 5 Either way, when a biopsy is obtained to confirm the diagnosis of ACD/MPV, consideration should be given to the possibility of uneven distribution of lesions. This is especially important if no other life-threatening co-malformations are found and the prognosis is based solely on the severity of lung lesions.
Treatment
Similar to persistent PH of the newborn (PPHN), the clinical approach to ACD/MPV consists of general supportive cardiorespiratory care and vasodilatory agents to reduce PH. In most cases, intubation and mechanical ventilation are immediately required at time of presentation due to the very low oxygen saturation levels. Rarely, only supplemental oxygen is temporarily enough to stabilize the patient before mechanical ventilation is needed. 4, 7, 10, 15, 17, 20, 37 To reduce the pulmonary vascular resistance, inhaled nitric oxide and oral or intravenous vasodilatory agents such as milrinone, sildenafil, or epoprostenol are used. In the short term, this can improve the saturation levels, but literature shows that the dosage needs to be increased repeatedly and that eventually the severe hypoxemia will be fatal. 4, 5, 7, 10, 18, 20, 22, 23, 37, 38 Interestingly, one atypical ACD/ MPV patient was still alive on oral vasodilators and supplemental oxygen at the age of 38 months when the case report was written. 21 ECMO therapy can be used to stabilize infants in lifethreatening conditions if the diagnosis is not clear. Yet, the vast majority of ACD/MPV patients cannot be weaned from ECMO, while ECMO itself is invasive, comes with risks of complications, and is expensive. 1, 4, 7, 8, 19, 23, 28, 29, 37 Ideally, an open lung biopsy is performed before ECMO therapy has started or at least before a ''second-run'' ECMO therapy is considered. 7, 14, 27, 28 On the other hand, ECMO therapy can provide an excellent bridge to lung transplantation in ACD/MPV patients with a mild phenotype. 12, 36 To date, seven ACD/MPV patients receiving bilateral lung transplantation have been reported in the United States with a comparable five-year survival (56%) to infants transplanted for other indications at the St. Louis Children's Hospital, Missouri. 36, 39 All of the transplanted ACD/MPV patients had an atypical milder phenotype than the classical ACD/MPV patients. 12, 36, 40 Although the overall survival in this young age group is still disappointing, ECMO therapy followed by lung transplantation is the potential treatment of choice for selected ACD/MPV patients.
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Pathogenesis
Although the pathogenesis of ACD/MPV has not yet been fully defined, several hypotheses implicating various factors and events have been proposed. It is thought that ACD/ MPV is caused by an early disturbance in embryonic lung development. Already at the end of the embryonic phase of lung development (five weeks of gestation), the two lung buds are surrounded by a vascular network that is connected to the systemic circulation. During the pseudoglandular phase (5-16 weeks of gestation), this network expands by angiogenesis when the two buds branch into the loose mesenchymal tissue. In the canalicular and saccular stage (16-26 and 26-38 weeks of gestation, respectively), expansion of the network continues, increasing the capillary density in the developing lung. 44, 45 The deficiency of capillaries in ACD/MPV lung tissue implies a disturbance already in the early embryonic and pseudoglandular phase. The presence of thickened septa and simplified acini with a reduced number of type 1 pneumocytes in ACD/MPV lungs indicate that also the saccular stage is affected, in which normally the alveolar saccules are formed with thin septa covered by type 1 pneumocytes. 35, 46, 47 The cause of PH in ACD/MPV is still a topic of discussion. It was suggested that chronic hypoxemia in the newborn induces hypertrophic arterial changes which cause PH. 35, 38 However, this seems unlikely because the extent of arterial changes in ACD/MPV newborns would imply the presence of hypoxemia already during early fetal life when the oxygen is still provided by the placenta. Moreover, this theory is inconsistent with the poor outcome of ACD/MPV patients despite mechanical ventilation or ECMO therapy which diminishes the hypoxemia. Another, more acceptable, theory is that the PH results from a marked reduction in the alveolar capillary bed. 18, 33 However, abrupt deterioration in late presenters without any signs of PH during the time before deterioration questions this theory as well. 4, 18, 23, 33, 34 Collectively, the progressive PH combined with structural histological changes in all ACD/MPV patients suggests a disturbance in normal pulmonary vascular development and is currently the subject of several studies in different laboratories.
The origin of the ''misaligned pulmonary veins'' found in peripheral ACD/MPV lung tissue, and whether they are indeed malpositioned, is not clear. Considering the presence of valves, it is more likely that the anomalous veins originate from bronchial veins that normally do not extend beyond the larger bronchopulmonary branches. [33] [34] [35] This theory is supported by a study showing ''misaligned pulmonary veins'' originating from bronchial veins and act as shunt vessels between the bronchial and pulmonary veins. 48 
Role of FOXF1 in ACD/MPV
In 2009, Stanckiewizc and Shaw-Smith suggested an association between ACD/MPV and haploinsufficiency of the Forkhead Box F1 (FOXF1) gene. 2 Since then, they have accumulated the largest ACD/MPV sample collection of 141 patients in which they identified 86 pathogenic variants containing copy number variations (CNVs), point mutations, and one complex rearrangement, all involving the FOXF1 gene or its regulatory region. 49 This regulatory region was identified by defining the shortest region of overlapping genomic deletions in ACD/MPV patients. 50, 51 The remaining 55 cases were not genetically tested due to insufficient DNA quality. 49 Additionally, a variety of heterozygous genomic variants in the FOXF1 locus of ACD/MPV patients have been reported by other research groups. 8, 16, 20 Most of the variants are collected in the Leiden Open Variation Database (LOVD). 52 FOXF1, first described by Pierrou et al. in 1994 , is a member of the Forkhead box transcription factors (TFs) and plays a role during embryonic development, specifically in lung development. 53 Studies in rodent embryos show that FOXF1 is already expressed at the primitive streak stage in the mesodermal lateral plate and continues to be expressed during development in mesenchymal lung tissue. [54] [55] [56] [57] [58] Very little is known about FOXF1 expression during human lung development, but in newborns FOXF1 is expressed in mesenchymal stromal cells from tracheal aspirates. 59 FOXF1 is regulated by Sonic hedgehog (SHH) signaling, one of the key regulators of embryonic development. 60 Further research on the signaling pathways involving FOXF1 is ongoing. A recent study showed that the serotonin transporter (SERT) protein, important during pulmonary vascular remodeling and adaptation at birth, might be one of the downstream targets of FOXF1 as the expression of SERT protein was completely absent in ACD/MPV patients while expression levels in other disorders causing PH in the newborn were normal. 61 Although rodent models enable us to study the function of FOXF1 during lung development, the phenotype of heterozygous FoxF1 mice does not completely correlate with ACD/MPV. Similar to ACD/MPV, heterozygous deletion of FoxF1 gives rise to multiple foregut and lung defects including lobular and alveolar underdevelopment, compact lung mesenchyme, and hemorrhagic lesions. However, the pulmonary branching defects dominate in these models while the main problem in ACD/MPV is the underdeveloped pulmonary vascularization. 62 These differences illustrate the difficulties of studying the pathogenesis of ACD/MPV.
Imprinting of FOXF1
The question why a heterozygous genomic alteration in the FOXF1 gene or its regulatory region causes haploinsufficiency and results in ACD/MPV is still unanswered. The most suggested and studied explanation is parental imprinting where epigenetic marks determine if a particular gene is only expressed on the paternal or maternal allele. 2, 50, 54, 63 Assuming this hypothesis is true, all genomic alterations associated with ACD/MPV would be located on the same parental chromosome. Indeed, all but one of the deletions located in the regulatory region did arise on the maternal chromosome. However, mutations located in the FOXF1 transcription region are found on both paternal and maternal alleles. Still, this might implicate parental imprinting of the regulatory region instead of the transcription region itself. 49 Unfortunately, detailed studies on imprinting of the FOXF1 locus in fetal, neonatal, and adult lung tissue have not been able to confirm this idea. 50, 64 Phenotypical differences of ACD/MPV Although earlier studies suggested a high correlation between ACD/MPV and genomic alterations in the FOXF1 locus, familial cases show large phenotypical differences and, again, illustrate the complexity of the molecular mechanisms causing ACD/MPV. In total, eight ACD/MPV families with associated genomic variants in the FOXF1 transcription region have been reported so far ( Fig. 2 ; Table 1) . 49, 63, 65, 66 In six of these families, the pathogenic variant was also found in one of the parents including two fathers who were mosaic. None of those parents exhibited signs of ACD/MPV. The phenotypical variance is also illustrated by family 6 (Fig. 2 ) that was previously described by Reiter et al. 66 In this family, two children were affected by ACD/MPV but only one of them showed classical features of ACD/MPV. The other child presented with an atypical form and survived. Interestingly, another sister carried the same mutation but was unaffected. 49, 66 The genotypephenotype variation might be associated with altered FOXF1 expression levels, similar to FoxF1 heterozygote knock-out mice that show variation in the phenotype severity correlated to FoxF1 expression levels. 58 Different expression levels can be the result of so-called ''modifier genes'' that modify the expression of the FOXF1 gene. In combination with mutations or deletions in the FOXF1 locus, alterations in these modifier genes might lead to ACD/MPV. This idea is supported by the finding that the survival of heterozygous FoxF1 knock-out mice depends on their genetic background. 62 Summary ACD/MPV is a rare, almost uniformly lethal, developmental disorder of the lungs. Patients suffer from severe hypoxemia and PH that progresses over time. Although the awareness of ACD/MPV is growing among clinicians, it can be confused with idiopathic PH as the clinical picture is similar. This prolongs the time to confirm the diagnosis and contributes to unnecessary suffering of patients and a high cost of therapy. As soon as the response to medical treatment deviates from the expected, a histological examination should be performed. Moreover, an open lung biopsy is ideally performed before ECMO therapy or surgical interventions for co-occurring anomalies are initiated. For a very small selection of atypical ACD/MPV patients, a lung transplantation can be considered although survival rates are still disappointing. ACD/MPV is associated with haploinsufficiency of FOXF1, a TF regulated by SHH that plays a significant role during early lung development. Although phenotypical differences are present, prenatal or postnatal genetic testing could contribute to earlier detection and allows adequate consultation about the prognosis and the process of decision-making.
